Adaptimmune Therapeutics Plc ADR (ADAP)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Adrian Rawcliffe
Employees:
490
60 JUBILEE AVENUE, MILTON PARK, ABINGDON, OXFORDSHIRE, UNITED KINGDOM OX14 4RX
44 1235 430000

Adaptimmune Therapeutics plc focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS)

Data derived from most recent annual or quarterly report
Market Cap 344.806 Million Shares Outstanding156.73 Million Avg 30-day Volume 584.021 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.04
Price to Revenue10.0144 Debt to Equity0.0 EBITDA-169.607 Million
Price to Book Value1.5496 Operating Margin-1024.0463 Enterprise Value-24.047 Million
Current Ratio3.997 EPS Growth-0.125 Quick Ratio3.049
1 Yr BETA 1.1493 52-week High/Low 4.28 / 1.01 Profit Margin-998.2551
Operating Cash Flow Growth93.5157 Altman Z-Score-4.193 Free Cash Flow to Firm -38.52 Million
View SEC Filings from ADAP instead.

View recent insider trading info

Funds Holding ADAP (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ADAP

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-11-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-08:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-25:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-09:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-15:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-25:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-04:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-14:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    RAWCLIFFE ADRIAN CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    3,316 2022-09-01 6

    LUNGER JOHN CHIEF PATIENT SUPPLY OFFICER

    • Officer
    4,829 2022-08-01 6

    PICCINA CINTIA CHIEF COMMERCIAL OFFICER

    • Officer
    34,824 2022-08-01 3

    MOTT DAVID M

    • Director
    1,000,439 2022-07-01 1

    DUNCAN BARBARA GAYLE

    • Director
    500,000 2022-07-01 1

    NOBLE JAMES

    • Director
    710,711 2022-07-01 1

    ALLEVA LAWRENCE M

    • Director
    816,067 2022-07-01 1

    BEHBAHANI ALI

    • Director
    737,050 2022-07-01 1

    SIGAL CHARLES ELLIOTT

    • Director
    737,050 2022-07-01 1

    ZAKS TAL ZVI

    • Director
    500,000 2022-07-01 1

    FUREY JOHN

    • Director
    500,000 2022-07-01 1

    WOOD GAVIN CHIEF FINANCIAL OFFICER

    • Officer
    96,000 2022-05-20 2

    BREWER JOANNA ELIZABETH CHIEF SCIENTIFIC OFFICER

    • Officer
    0 2022-05-04 2

    BERTRAND WILLIAM C JR CHIEF OPERATING OFFICER

    • Officer
    7,336 2022-01-18 4

    NORRY ELLIOT CHIEF MEDICAL OFFICER

    • Officer
    3,529 2022-01-18 4

    TAYTON-MARTIN HELEN KATRINA CHIEF BUSINESS OFFICER

    • Officer
    1,721,328 2022-01-12 1

    SANDELL SCOTT D

    • 10% Owner
    102,478,668 2020-01-24 0

    BASKETT FOREST

    • 10% Owner
    102,478,668 2020-01-24 0

    SONSINI PETER W.

    • 10% Owner
    102,478,668 2020-01-24 0

    FLORENCE ANTHONY A. JR.

    • 10% Owner
    102,478,668 2020-01-24 0

    GARONE MICHAEL INTERIM CFO

    • Officer
    0 2019-10-01 0

    AMADO RAFAEL PRESIDENT, R&D

    • Officer
    17,237 2019-08-06 0

    KERR GILES FRANCIS BERTRAM

    • Director
    0 2019-07-02 0

    BINDER-SCHOLL GWENDOLYN KNOWLTON CHIEF TECHNOLOGY OFFICER

    • Officer
    2,487 2019-01-14 0

    BARRIS PETER J

    • 10% Owner
    94,978,668 2018-09-07 0

    BARRETT M JAMES

    • 10% Owner
    82,978,668 2018-09-07 0

    KERINS PATRICK J

    • 10% Owner
    82,978,668 2018-09-07 0

    VISWANATHAN RAVI

    • 10% Owner
    94,978,668 2018-09-07 0

    NEW ENTERPRISE ASSOCIATES 14, L.P.

    NEA PARTNERS 14, L.P.

    NEA 14 GP, LTD

    • 10% Owner
    82,978,668 2018-09-07 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP V LLC

    • Director
    4,901,310 2018-06-04 0

    THOMPSON PETER A.

    • Director
    4,901,310 2018-06-04 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP V LLC

    ISALY SAMUEL D

    • Director
    6,149,377 2017-03-27 0

    LAING IAN MICHAEL

    • Director
    0 2016-08-11 0

    KNOWLES JONATHAN KENNETH CHARLES

    • Director
    0 2016-08-11 0

    KOLLURI KRISHNA KITTU

    • 10% Owner
    59,269,000 2016-01-01 0

    WELLER HARRY R

    • 10% Owner
    59,269,000 2016-01-01 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2022-11-25 22:15:03 UTC 3.0166 0.8034 900000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2022-11-25 21:45:04 UTC 3.0166 0.8034 900000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2022-11-25 21:15:03 UTC 3.0166 0.8034 900000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2022-11-25 20:45:03 UTC 3.0166 0.8034 900000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2022-11-25 20:15:03 UTC 3.0166 0.8034 900000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2022-11-25 19:45:04 UTC 3.0166 0.8034 900000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2022-11-25 19:15:03 UTC 3.0166 0.8034 900000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2022-11-25 18:45:03 UTC 3.0166 0.8034 900000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2022-11-25 18:15:03 UTC 3.0166 0.8034 900000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2022-11-25 17:45:04 UTC 3.0166 0.8034 900000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2022-11-25 17:15:03 UTC 3.0166 0.8034 900000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2022-11-25 16:45:04 UTC 3.0961 0.7239 900000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2022-11-25 16:15:03 UTC 3.0961 0.7239 900000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2022-11-25 15:45:03 UTC 3.0961 0.7239 900000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2022-11-25 15:15:03 UTC 3.0961 0.7239 900000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2022-11-25 14:45:04 UTC 3.0961 0.7239 900000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2022-11-25 14:15:04 UTC 3.0961 0.7239 900000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2022-11-25 13:45:03 UTC 3.0963 0.7237 900000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2022-11-25 13:15:03 UTC 3.0963 0.7237 900000
    ADAPTIMMUNE THERAPEUTICS-ADR ADAP 2022-11-25 12:45:03 UTC 3.0963 0.7237 900000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund ADAP -6300.0 shares, $-6772.5 2022-09-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments